Company Profile

RemeGen Company Limited (OTC: REGMY)
Pricing data not available
Detailed Quote
Open: $ n/a   Volume: n/a
High: $ n/a   Yield(%) n/a
Low: $ n/a   P/E Ratio (ttm): n/a
Dividend ($): n/a   Market Cap ($): n/a
EPS ($) n/a   Shares Out: n/a
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): -11.91
% Price Change (last 13 weeks): -18.12
% Price Change (last 26 weeks): -35.79
% Price Change (last 52 weeks): -33.67
% Price Change (year to date): -39.74
Management Effectiveness
Return on Equity (%): -35.52
Return on Assets (%): -25.92
Return on Invested Capital (%): -35.15
Profitability
Gross Profit Margin (%): 60.80
Net Profit Margin (%): -140.62
Operating Profit Margin (%): -146.97
Price & Volume
50-day Moving Average: $n/a
200-day Moving Average: $n/a
Avg. Daily Vol. (last 50 days): n/a
Avg. Daily Vol. (last 200 days): n/a
52-wk high: $n/a
52-wk low: $n/a
Bid: $n/a
Ask: $n/a
Company Information
RemeGen Co., Ltd. is a biopharmaceutical company. It discovers, develops and commercializes biologics for the treatment of autoimmune, oncology, and ophthalmic diseases. The company was founded by Dr. Jianmin Fang and Wang Weidong on July 04, 2008 and is headquartered in Yantai, China.
RemeGen Company Limited
No. 58, Beijing Middle Road Yantai Development Zone
Yantai SD 264006

Phone: 86.535.6113513
Fax: 86.535.6113517
http://www.remegen.com
Per Share Data
Earnings (1year) ($): -0.40
Annual Dividend ($): 0.00
Current P/E Ratio (ttm): n/a
Book Value ($): 0.90
Cash Flow ($): -0.52
Valuation Ratios
Price/Earnings (x): n/a
Price/Sales (x): 17.01
Price/Book (x): 5.32
Price/Cash Flow (x): n/a
Financial Strength
Quick Ratio (x): 1.32
Current Ratio (x): 1.98
LT Debt/Equity (x): 26.63
Total Debt/Equity (x): 37.06



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2020 Wall Street Horizon, Inc.